September 2019

Trial Targets Options for
Urothelial Carcinoma

After a patient fails platinum-based first-line therapy and immunotherapy, there are currently no other options for treating urothelial cancer. A study looked at a new targeting agent, enfortumab vedotin, that targets nectin-4 (a protein found in urothelial cancer). The study found that the overall survival time was 11.7 months, which could provide more treatment options; however, larger studies are needed. Read more.


Lower Filgrastim Dose for
Chemo-Induced Neutropenia

Filgrastim (Neupogen) comes in two vial sizes: 300 mcg and 480 mcg. The dosage for preventing neutropenia is 5 mcg/kg. Since the drug comes in only two vial sizes, some patients are under-dosed. Elsayed and colleagues found that patients weighing 85 kg and less benefit from using a suboptimal dose versus patients who weigh greater than 85 kg who benefit from the higher dose. Read more.

Pembrolizumab Indication for Small-Cell Lung Cancer?
An accelerated FDA approval was granted to pembrolizumab for treating patients with metastatic small-cell lung cancer who have progressed following platinum-based chemotherapy. Two trials, KEYNOTE-158 and KEYNOTE-028, validated this approval. However, a confirmatory trial is underway, and if the trial proves what the two KEYNOTE studies demonstrated, then small-cell lung cancer treatment protocols will potentially be updated. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App